Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Aarti Drugs Limited - Updates

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Spurt in Volume

2018-06-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Reply to Clarification- Financial results

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Clarification - Financial Results

2018-05-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Press Release

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Financial Result Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Change in Auditors

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Aarti Drugs Limited - Dividend

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

31
Market Live: Nifty extends losses, Sensex falls over 250 pts; Bank index dips 1%

2018-05-16 moneycontrol
RBI Intervention: The Reserve Bank of India (RBI) likely intervened heavily in the foreign exchange market right from the start of trade on Wednesday to stem any fall in the rupee, three dealers said.
HD WELSPUNIND BHUSANSTL BRIGADE IDBI KTKBANK 532712 532832 PRAJIND 531431 SYNDIBANK 532343 500470 533207 532121 RCOM 532461 CENTURYPLY 532480 500477 524348 500055 ASHOKLEY 522205 514162 UBNC 532929 500116 TVSMOTOR ALBK 532505 532548 AKLD 532652 532276 TTST PNJZY TATASTEEL JPINFRATEC TATLY AARTIDRUGS PNB UCOBANK DENABANK AKLS IBREALEST SHAKTIPUMP

14
ITC, Hindalco, JSW Steel results on Wednesday

2018-05-15 thehindubusinessline
Over 60 companies including Aarti Drugs, Alembic Pharma, Axis Bank, AIA Engineering, Balkrishna Paper, Brigade Enterprises, Birla Corp, Career Point, DB Corp, Dishman Carbogen, Gateway Distriparks, Geojit, GSFC, Hindalco, ITC, JSW Steel, Jyothy Labs, Muthoot Finance, Nesco, NIIT, Punjab & Sind Bank, PTC India, Prataap Snacks, Teamlease, TVS Motor, Welspun India and Zee Media will declare their quarter/full-year results for FY18 on Wednesday.
AIAENG WELSPUNIND MUTHOOTFIN 500228 BRIGADE 533398 532215 532343 532683 AXISBANK CAREERP 524348 514162 532929 TVSMOTOR AXB 533260 PTC 532524 532622 JSWSTEEL AXBKY AXBA GDL AARTIDRUGS AAGGY

0
Aarti Drugs Limited - Trading Window

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AARTIDRUGS 524348

0
Anti-dumping duty imposed on Ofloxacin imports from China

2018-03-18 thehindubusinessline
India has imposed anti-dumping duty on import of Chinese pharma product, used in the treatment of certain infections, to protect domestic producers from below-cost shipments.
AARTIDRUGS 524348

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...